PharmaLundensis AB:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:PharmaLundensis AB - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C11507
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:22
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:スウェーデン
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥33,750見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥67,500見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥101,250見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
PharmaLundensis AB (PharmaLundensis) is a pharmaceutical company that develops drugs for lung diseases. The company develops drugs for chronic obstructive pulmonary disease (COPD), chronic bronchitis and influenza-induced lung failure. It also develops EcoFilter, a system that that eliminates all the release of pharmaceutical drugs and multi-resistant bacteria in hospital waste water and removes all multi-resistant bacteria from hospital sewage pipes, thereby eliminating the risk of multi-resistant bacteria that are growing in the pipes can infect patients in the hospital wards. The company conducts research on lung physiology and pathology to ascertain pharmacological modification applications to treat pulmonary diseases. PharmaLundensis is headquartered in Lund, Sweden.

PharmaLundensis AB – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
PharmaLundensis AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
PharmaLundensis AB, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
PharmaLundensis AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
PharmaLundensis AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
PharmaLundensis AB, Medical Devices Deals, 2012 to YTD 2018 9
PharmaLundensis AB, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
PharmaLundensis AB, Pharmaceuticals & Healthcare, Deal Details 11
Equity Offering 11
PharmaLundensis to Raise USD1.2 Million in Rights Offering of Shares 11
PharmaLundensis Raises USD1 Million in Rights Offering of Shares 12
PharmaLundensis Raises USD0.9 Million in Public Offering of Shares 13
PharmaLundensis Raises USD0.4 Million in Public Offering of Shares 14
PharmaLundensis AB – Key Competitors 15
PharmaLundensis AB – Key Employees 16
PharmaLundensis AB – Locations And Subsidiaries 17
Head Office 17
Recent Developments 18
Financial Announcements 18
Feb 16, 2018: PharmaLundensis: Financial Statement 1 January 2017 to 31 December 2017 18
May 24, 2017: PharmaLundensis: Annual Report 2016 19
Other Significant Developments 21
Jul 13, 2017: Pharmalundensis: Valuation of the project’s economic potential 21
Appendix 22
Methodology 22
About GlobalData 22
Contact Us 22
Disclaimer 22

List of Tables
PharmaLundensis AB, Pharmaceuticals & Healthcare, Key Facts 2
PharmaLundensis AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
PharmaLundensis AB, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
PharmaLundensis AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
PharmaLundensis AB, Deals By Therapy Area, 2012 to YTD 2018 8
PharmaLundensis AB, Medical Devices Deals, 2012 to YTD 2018 9
PharmaLundensis AB, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
PharmaLundensis to Raise USD1.2 Million in Rights Offering of Shares 11
PharmaLundensis Raises USD1 Million in Rights Offering of Shares 12
PharmaLundensis Raises USD0.9 Million in Public Offering of Shares 13
PharmaLundensis Raises USD0.4 Million in Public Offering of Shares 14
PharmaLundensis AB, Key Competitors 15
PharmaLundensis AB, Key Employees 16

List of Figures
PharmaLundensis AB, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
PharmaLundensis AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
PharmaLundensis AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
PharmaLundensis AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
PharmaLundensis AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
PharmaLundensis AB, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
PharmaLundensis AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
PharmaLundensis AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
PharmaLundensis AB, Medical Devices Deals, 2012 to YTD 2018 9

★海外企業調査レポート[PharmaLundensis AB:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Taisei Lamick Co., Ltd.:企業の戦略・SWOT・財務情報
    Taisei Lamick Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Taisei Lamick Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Gore Mutual Insurance Company:企業の戦略・SWOT・財務情報
    Gore Mutual Insurance Company - Strategy, SWOT and Corporate Finance Report Summary Gore Mutual Insurance Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • AirAsia Berhad:戦略・SWOT・企業財務分析
    AirAsia Berhad - Strategy, SWOT and Corporate Finance Report Summary AirAsia Berhad - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • Paratek Pharmaceuticals Inc (PRTK):製薬・医療:M&Aディール及び事業提携情報
    Summary Paratek Pharmaceuticals Inc (Paratek) is a biopharmaceutical company that develops and commercializes therapies based on tetracycline chemistry. Omadacycline (antibiotic), the company’s lead product candidate is an aminomethylcycline which acts against gram-negative, gram-positive, and atypi …
  • Litani River Authority:企業の戦略的SWOT分析
    Litani River Authority - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • Orchid Pharma Ltd (ORCHIDPHAR):製薬・医療:M&Aディール及び事業提携情報
    Summary Orchid Pharma Ltd (Orchid), formerly Orchid Chemicals & Pharmaceuticals Ltd is a pharmaceutical company that develops and manufactures pharmaceutical solutions such as formulations and API products. The company offers formulations such as cardiovascular products, neuropsychiatry products, an …
  • South Egypt Drug Industries Co:企業の戦略的SWOT分析
    South Egypt Drug Industries Co - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major prod …
  • Volkswagen AG (VOW3)-エネルギー分野:企業M&A・提携分析
    Summary Volkswagen AG (Volkswagen) is an automobile company involved in the design, development, production and sales of a wide range of vehicles and engines. It commercializes both passenger and commercial vehicles, including low consumption small cars and luxury class vehicles. The company sells i …
  • Danfoss AS:企業の戦略的SWOT分析
    Danfoss AS - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. T …
  • Ineos Group AG:企業の戦略的SWOT分析
    Ineos Group AG - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and service …
  • Seair Inc:企業の戦略的SWOT分析
    Seair Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. Th …
  • Chemetall GmbH:企業の戦略的SWOT分析
    Chemetall GmbH - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and service …
  • Cantabio Pharmaceuticals Inc (CTBO):製薬・医療:M&Aディール及び事業提携情報
    Summary Cantabio Pharmaceuticals Inc (Cantabio Pharmaceuticals) is a biotechnology company that concentrates on the commercializing of novel therapies for Parkinson’s disease, Alzheimer’s disease and neurodegenerative diseases. The company provide pipeline product candidates such as CB101 and CB102, …
  • Lipocine Inc (LPCN):製薬・医療:M&Aディール及び事業提携情報
    Summary Lipocine Inc (Lipocine) is a pharmaceutical company that develops and commercializes treatment for men's and women's health. The company’s pipeline products for men’s health include LPCN 1111 and LPCN 1021; and for women’s health include LPCN 1107. Its LPCN 1111 is an oral testosterone produ …
  • CFM International, Inc.:企業の戦略・SWOT・財務情報
    CFM International, Inc. - Strategy, SWOT and Corporate Finance Report Summary CFM International, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Melrose Industries PLC (MRO):企業の財務・戦略的SWOT分析
    Summary Melrose Industries PLC (Melrose) is an investment company that improve and sell industrial and manufacturing businesses. The company offers products such as air management, security, home automation and ergonomic and electricity generating equipment. Its business portfolio comprises of Norte …
  • Abionic SA:医療機器:M&Aディール及び事業提携情報
    Summary Abionic SA (Abionic) is a medical device company that develops, produces, and markets in vitro diagnostic devices. The company provides products such as abioSCOPE, IVD capsule, abioGUIDE, abioGUIDE application for android, iPhone and iPad, and accessories, among others. Its abioSCOPE in vitr …
  • Uptake Medical Corp-製薬・医療分野:企業M&A・提携分析
    Summary Uptake Medical Corp (Uptake Med) is a healthcare technology company that develops medical technologies for the treatment of emphysema and lung cancer. The company develops intervapor therapy system, a bronchoscopic procedure in which heated water vapor is delivered to emphysematous lung tiss …
  • Biohaven Pharmaceutical Holding Company Ltd (BHVN):製薬・医療:M&Aディール及び事業提携情報
    Summary Biohaven Pharmaceutical Holding Company Ltd (Biohaven), a subsidiary of Portage Biotech Inc, is a clinical-stage biopharmaceutical company that develops late-stage product candidates for neurological diseases. The company develops small molecule CGRP receptor antagonist platform that include …
  • Hunting PLC (HTG):企業の財務・戦略的SWOT分析
    Hunting PLC (HTG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆